Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Income towards Parent Company: 2014-2024

Historic Income towards Parent Company for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$208.0 million.

  • Spyre Therapeutics' Income towards Parent Company rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.60% up from last year.
  • As of FY2024, Spyre Therapeutics' Income towards Parent Company stood at -$208.0 million, which was up 38.60% from -$338.8 million recorded in FY2023.
  • Over the past 5 years, Spyre Therapeutics' Income towards Parent Company peaked at -$65.8 million during FY2021, and registered a low of -$338.8 million during FY2023.
  • Its 3-year average for Income towards Parent Company is -$210.2 million, with a median of -$208.0 million in 2024.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 304.21% in 2023, then skyrocketed by 38.60% in 2024.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Income towards Parent Company stood at -$80.9 million in 2020, then rose by 18.66% to -$65.8 million in 2021, then declined by 27.38% to -$83.8 million in 2022, then tumbled by 304.21% to -$338.8 million in 2023, then soared by 38.60% to -$208.0 million in 2024.